<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04304352</url>
  </required_header>
  <id_info>
    <org_study_id>IEO S582/111 RE324/2</org_study_id>
    <nct_id>NCT04304352</nct_id>
  </id_info>
  <brief_title>Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients</brief_title>
  <acronym>VEX</acronym>
  <official_title>A Phase II Study of Metronomic Oral Chemotherapy With Cyclophosphamide Plus Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Institute of Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study assessing the activity and safety of metronomic chemotherapy with&#xD;
      cyclophosphamide and capecitabine and vinorelbine in advanced breast cancer patient in four&#xD;
      different cohort of patients:&#xD;
&#xD;
        1. Untreated (naïve) patients with endocrine responsive disease&#xD;
&#xD;
        2. Pretreated patients with endocrine responsive disease&#xD;
&#xD;
        3. Untreated (naïve) patients with triple negative disease&#xD;
&#xD;
        4. Pretreated patients with triple negative disease The primary endpoint will be the&#xD;
           progression-free survival&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an institutional, monocentric, open-label, phase II study of oral &quot;metronomic&quot;&#xD;
      Vinorelbine plus Capecitabine and Cyclophosphamide (VEX) in patients with advanced breast&#xD;
      cancer .&#xD;
&#xD;
      Patients will receive the combination regimen as follow:&#xD;
&#xD;
      Cyclophosphamide 50 mg daily Capecitabine 500 mg, thrice daily Vinorelbine 40 mg orally&#xD;
      thrice a week&#xD;
&#xD;
      Four independent cohorts of patients will be evaluated in the study:&#xD;
&#xD;
        1. Untreated (naïve) patients with endocrine responsive disease&#xD;
&#xD;
        2. Pretreated patients with endocrine responsive disease&#xD;
&#xD;
        3. Untreated (naïve) patients with triple negative disease&#xD;
&#xD;
        4. Pretreated patients with triple negative disease Combination will be administered until&#xD;
           disease progression or unacceptable toxicity.&#xD;
&#xD;
      The primary endpoint will be to assess the Time to progression (TTP) of VEX combination in&#xD;
      the four different cohorts&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2011</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>28 days</time_frame>
    <description>the time between the first study dose administration and the date of progression of the disease or cancer-related death, whichever occurs first</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Metronomic VEX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metronomic VEX (Oral Cyclophosphamide 50 mg daily continuous, Oral Capecitabine 500 mg, thrice daily continuous, Oral Vinorelbine 40 mg day 1,3 and 5 every week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>Metronomic Vinorelbine 40 mg orally thrice a week</description>
    <arm_group_label>Metronomic VEX</arm_group_label>
    <other_name>Metronomic Vinorelbine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Metronomic Capecitabine 500 mg, thrice daily</description>
    <arm_group_label>Metronomic VEX</arm_group_label>
    <other_name>Metronomic Capecitabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Metronomic Cyclophosphamide 50 mg daily</description>
    <arm_group_label>Metronomic VEX</arm_group_label>
    <other_name>Metronomic Cyclophosphamide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pre- or post-menopausal women (age ≥18 years) with histologically or cytologically&#xD;
             (cell block) proven, locally advanced (inoperable) or metastatic breast carcinoma.&#xD;
             Immunohistochemical evaluation of estrogen receptor (ER), progesterone receptor (PgR),&#xD;
             human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor&#xD;
             (EGFR) according to European Institute of Oncology guidelines is mandatory.&#xD;
&#xD;
          2. Patients with HER2 overexpressed tumors, are eligible if they had received previous&#xD;
             trastuzumab therapy for advanced disease, and/or a treatment with anti HER2 targeted&#xD;
             therapy.&#xD;
&#xD;
          3. Patients fulfilling one of the following criteria:&#xD;
&#xD;
               -  Patients with measurable disease as per RECIST 1.1 criteria. This is defined as&#xD;
                  at least one lesion that can be accurately measured in at least one dimension&#xD;
                  (longest diameter to be recorded) as 20 mm with conventional techniques or as 10&#xD;
                  mm with spiral CT scan&#xD;
&#xD;
               -  Patients with bone lesions, lytic or mixed (lytic + sclerotic), in the absence of&#xD;
                  measurable disease as defined by RECIST 1.1 criteria. Bone lesions must be&#xD;
                  evaluable by plain CT or MRI. Patients with lesions identified only on&#xD;
                  radionucleotide bone scan are not eligible.&#xD;
&#xD;
          4. Patients may have received any primary and/or adjuvant therapies, as any previous&#xD;
             lines of chemotherapy and endocrine therapy for advanced disease. Patients may have&#xD;
             received metronomic capecitabine, methotrexate and cyclophosphamide in adjuvant&#xD;
             setting at least 12 months before study entry&#xD;
&#xD;
          5. Previous treatment with capecitabine, cyclophosphamide and vinorelbine not in&#xD;
             metronomic schedule for advanced disease is allowed, provided that the patient has&#xD;
             progressive disease at study entry and the patients should not be defined as&#xD;
             &quot;refractory&quot; to treatments (Pathological Response or Complete Response or Stable&#xD;
             Disease &gt; 6 months).&#xD;
&#xD;
          6. Patients may have had previous hormonal therapy as treatment of metastatic disease&#xD;
             provided that the patient has progressive disease at study entry. Hormonal therapy&#xD;
             must be discontinued prior to study entry, excluding Luteinizing Hormone-Releasing&#xD;
             Hormone (LHRH) analogue.&#xD;
&#xD;
          7. Life expectancy greater than 6 months.&#xD;
&#xD;
          8. Eastern Cooperative Oncology Group (ECOG) Performance Status performance status &lt;2&#xD;
&#xD;
          9. Patients must have normal organ and marrow function as defined below:&#xD;
&#xD;
               -  leukocytes ≥ 3,000/μL&#xD;
&#xD;
               -  absolute neutrophil count ≥ 1,000/μL&#xD;
&#xD;
               -  platelets ≥ 100,000/μL&#xD;
&#xD;
               -  Haemoglobin ≥ 10 g/dl&#xD;
&#xD;
               -  total bilirubin within normal institutional limits&#xD;
&#xD;
               -  Aspartate Aminotransferase (AST)/Alanine Aminotransferase (ALT) ≤ 2 X&#xD;
                  institutional upper limit of normal&#xD;
&#xD;
               -  creatinine within normal institutional limits OR&#xD;
&#xD;
               -  creatinine clearance ≥ 60 mL/min/1.73 m for patients with creatinine levels above&#xD;
                  institutional normal&#xD;
&#xD;
         10. Geographically accessible for follow up.&#xD;
&#xD;
         11. Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous metronomic chemotherapy for advanced disease with capecitabine,&#xD;
             cyclophosphamide and vinorelbine&#xD;
&#xD;
          2. Patients defined as &quot;refractory&quot; to capecitabine, cyclophosphamide and vinorelbine&#xD;
             (Progression Disease or Stable Disease &lt; 6 months).&#xD;
&#xD;
          3. Presence of symptomatic cerebral or leptomeningeal involvement.&#xD;
&#xD;
          4. Previous or concomitant other malignancy except basal or squamous cell carcinoma of&#xD;
             the skin or adequately treated in situ carcinoma of the cervix.&#xD;
&#xD;
          5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          6. Malabsorption syndrome or disease affecting significantly gastrointestinal function or&#xD;
             major resection of the stomach or proximal small bowel that could affect absorption of&#xD;
             oral vinorelbine&#xD;
&#xD;
          7. Concurrent treatment with any other anti-cancer therapy except LHRH analogue.&#xD;
&#xD;
          8. Patients with pre-existing motor or sensory peripheral neuropathy grade 2 according to&#xD;
             NCI criteria&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Colleoni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>European Institute of Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilia Montagna, MD</last_name>
    <phone>+390257489243</phone>
    <email>emilia.montagna@ieo.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claudia A Sangalli</last_name>
    <phone>+390257489840</phone>
    <email>claudia.sangalli@ieo.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>European Institute of Oncology</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilia Montagna, MD</last_name>
      <phone>+390257489</phone>
      <phone_ext>243</phone_ext>
      <email>emilia.montagna@ieo.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2020</study_first_posted>
  <last_update_submitted>April 24, 2020</last_update_submitted>
  <last_update_submitted_qc>April 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

